LeukaemiaPhase 2MAC UCBTNCT02310997
Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)
A Phase 2 study testing Umbilical Cord Blood Transplant, Cyclophosphamide and Total body irradiation in people with Leukaemia and Lymphoma, run by University College, London at 12 sites in United Kingdom.
Trial summary
This trial is looking at using umbilical cord blood from unrelated donors after high dose chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system including leukaemia and lymphoma, or a blood disorder called myelodysplastic syndrome (MDS). Read more about this study
- Who is it for?
- Ages 28 days to 45 years
- Conditions the study is for
- Leukaemia, Lymphoma, Other Haematological Diseases
- What is being tested?
- Umbilical Cord Blood Transplant, Cyclophosphamide and Total body irradiation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 11 participants
- Where
- 12 sitesUnited Kingdom
- Study dates
- Jul 2011to May 2015
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 28 days to 45 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Subjects must be < 45 years of age and ≥ 28 days old
- Patients with high risk, advanced or poorly responding haematological disease for which there is published evidence that haematopoietic stem cell transplantation using myeloablative conditioning is likely to be effective
- The individual patient's disease status is such that there is no alternative therapy likely to achieve cure or provide a significant prolongation of disease-free survival
- Left ventricular ejection fraction >45%
- Transaminases and bilirubin < twice the upper limit of the normal range
- Creatinine clearance > 60mls/min
- Comorbidity index of 0 or 1
Who cannot join
- Patients with a suitably matched sibling donor or 10/10 unrelated volunteer donor available within an acceptable time period.
- Pregnancy or breastfeeding.
- Evidence of HIV or HTLV (I+II) infection or known HIV or HTLV positive serology
- Current active serious infection, in particular uncontrolled fungal infection -Previous irradiation that precludes the safe administration of an additional dose of 13- 14.4 Gy of total body irradiation (TBI) in patients aged 2-45 years
- Prior autograft
- CML in first chronic phase responding to Imatinib or refractory blast crisis
Show all 11Show fewer
- Patients with acute leukaemia in morphological relapse/ persistent disease (defined as > 5% blasts in normocellular bone marrow)
- Patients with acute myeloid leukaemia with relapse/persistent disease unresponsive to re-induction chemotherapy (defined as >20% blasts in normocellular bone marrow)
- Malignant disease that is refractory to or progressive on salvage therapy
- Myelofibrosis.
- Aplastic anaemia
Trial locations and contacts
12 sites in 1 country.
12 sites in 1 country
United Kingdom12 sites
University Hospital Birmingham
Birmingham, B15 2TH
Bristol Haematology & Oncology Centre
Bristol, BS2 8ED
Addenbrooke's Hospital
Cambridge, CB2 0QQ
St James' University Hospital
Leeds, LS9 7TF
University College London Hospital
London, Greater London, W1T 4TJ
St Bartholomew's Hospital
London, EC1A 7BE
Great Ormond Street Hospital for Children
London, WC1N 3JH
Manchester Royal Infirmary
Manchester, M13 9WL
Christie Hospital NHS Foundation Trust
Manchester, M20 4BX
Nottingham City Hospital
Nottingham, NG5 1PB
Royal Hallamshire Hospital
Sheffield, S10 2JF
Royal Marsden Hospital
Sutton, SM2 5PT
About this study
Official title: Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen
This trial is looking at using umbilical cord blood from unrelated donors after high dose chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system including leukaemia and lymphoma, or a blood disorder called myelodysplastic syndrome (MDS).
The trial is for babies over 4 weeks old, children, and adults up to the age of 45.
Read the detailed description
During treatment for cancers of the bone marrow or lymphatic system, a lot of the stem cells are damaged and you may need a bone marrow or stem cell transplant to replace them.
Stem cells can also be collected from the umbilical cord of newborn babies. Many people around the world have donated their baby's umbilical cords which are stored safely.
There are usually enough cells in one cord to transplant a small child, but there may not be enough cells for an older child or adult. Researchers want to see if adults and children can safely have stem cells from more than 1 umbilical cord.
Before a transplant, you have high doses of chemotherapy, sometimes with radiotherapy. This intensive conditioning aims to destroy all the cells in your bone marrow, and is called myeloablative conditioning.
The aim of this trial is to see if a transplant using cord blood cells from unrelated donors after myeloablative conditioning is safe, and whether it helps people who need a stem cell transplant but don't have a stem cell donor.
You may be able to enter this trial if you:
- Have leukaemia, lymphoma or another disorder of the bone marrow and treatment with intensive conditioning followed by a stem cell transplant is likely to help you
- Do not have a suitable stem cell donor in your family, and your doctors have not been able to find a matched unrelated donor
- Have satisfactory blood test results
- Are between 4 weeks and 45 years old
You cannot enter this trial if you:
- Have a family member who could donate stem cells to you, or you have a matched unrelated donor
- Can have any other treatment that your doctors think will cure your disease or keep it under control for a long time
- Have already had a lot of radiotherapy (the trial doctor can advise you about this)
- Have already had a bone marrow or stem cell transplant using your own cells
- Have chronic myeloid leukaemia that is in chronic phase and is responding to imatinib, or is in blast phase and is not responding to treatment Have acute lymphoblastic leukaemia that is not responding to treatment or has come back and more than 5% of your bone marrow is made up of immature cells (blasts)
- Have acute myeloid leukaemia that is not responding to treatment or has come back and more than 20% of your bone marrow is made up of immature cells (blasts)
- Have a disease that has come back and you are having another type of treatment (salvage treatment) but your disease is not responding or is getting worse
- Have a blood disorder called myelofibrosis
- Have a blood disorder called aplastic anaemia
- Have an infection that cannot be controlled with medication
- Have either the HIV or HTLV virus
- Are pregnant or breastfeeding
This phase 2 trial aims to recruit 60 people. It will include both adults and children. Everybody taking part will have intensive conditioning before having a transplant of stem cells from the umbilical cord blood of at least 1 unrelated donor.
To take part in this trial, the researchers need to be sure that there are 2 lots of cord blood cells that would be suitable for you. They will only use cells from 2 cords if there is some concern that they won't get enough cells from 1 umbilical cord.
People aged between 2 and 45 (apart from children under the age of 16 who have acute myeloid leukaemia, juvenile myelomonocytic leukaemia (JMML) or MDS) will have conditioning with fludarabine, cyclophosphamide and radiotherapy to the whole body (total body irradiation). This takes 9 days all together. On the last day, you have the stem cells through a drip into a vein.
Children under 2 years of age (and children up to the age of 16 who have acute myeloid leukaemia, JMML or MDS) will have conditioning with busulfan, cyclophosphamide and melphalan. They do not have radiotherapy. This conditioning takes 10 days all together. They have the stem cells through a drip into a vein on the 11th day.
The stem cells find their way into your bone marrow where they will start making new blood cells.
You will see the trial team and have some tests before you start treatment. The tests include:
- Physical examination
- Blood tests
- Chest X-ray
- Lung function tests
- Heart trace (ECG)
- Heart ultrasound (echocardiogram) or MUGA scan
- Bone marrow test When you have your treatment, you will be in hospital for about 4 to 6 weeks. As you will be at a high risk of infection, you will be in your own room. This is called being in isolation. You have another bone marrow test a month after your transplant.
When you go home, you have to go back to the hospital for regular blood tests. This is likely to be 2 or 3 times a week to begin with. You may have to go back into hospital for a few days at some point.
After a transplant, you will see the doctors and have blood tests At least once a week for the first 3 months At least once a month for the rest of the first year The trial doctors will follow your progress closely for at least 2 years.
The main side effect of the treatment you have just before the transplant is a drop in the number of blood cells, causing an increased risk of infection, tiredness and breathing problems.
We have more information about fludarabine, cyclophosphamide, busulfan and melphalan in our cancer drugs section.
It takes longer for blood cells to start growing again after a transplant of cord blood than after other types of stem cell transplant. Even when your blood count gets back to normal, your immune system may take up to 2 years to recover fully.
Unfortunately, this treatment can affect your ability to have children (your fertility). Men taking part will be offered the option to store sperm (sperm banking) before starting treatment. Preserving fertility for women is more complicated and it is important that women talk to their doctors about this before starting treatment.
After any type of bone marrow or stem cell transplant, there is a risk of graft versus host disease (GVHD). This happens when the new stem cells attack your body tissue. It mainly affects your skin, gut and liver.
Rarely, the new stem cells fail to start working. This is more common with cord blood transplants than with other bone marrow transplants. And even if your transplant is successful, there is a risk your disease may come back. Because of these risks, your doctors will monitor you very closely after your transplant.
- Conditions
- Leukaemia, Lymphoma, Other Haematological Diseases
- Being tested
- Umbilical Cord Blood Transplant, Cyclophosphamide, Total body irradiation, Busulfan, Melphalan
- Medical subject headings
- Leukemia, Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Umbilical Cord Blood TransplantOther
CyclophosphamideDrug
Total body irradiationRadiation
BusulfanDrug
MelphalanDrug
FludarabineDrug
| Study group | Role | What they receive |
|---|---|---|
| Fludarabine + Cyclophosphamide + TBI | Experimental | Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:
Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions Receives: Other: Umbilical Cord Blood Transplant; Drug: Cyclophosphamide; Radiation: Total body irradiation; Drug: Fludarabine |
| Busulfan + Cyclophosphamide + Melphalan | Experimental | Patients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:
Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2 Receives: Other: Umbilical Cord Blood Transplant; Drug: Cyclophosphamide; Drug: Busulfan; Drug: Melphalan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Non-relapse mortality at 100 days post transplant
Measured: 100 days post transplant
Secondary outcomes (5)
Overall survival at 1 year
Measured: 1 year post transplant
Time course of mixed chimerism established by the donor graft
Measured: 28, 60, 100 days, 6 months, 1 year post transplant
Recovery from neutropenia and cytopenia
Measured: up to 1 year post transplant
Incidence of acute and chronic GVHD
Measured: 100 Days and 1 year post transplant
Incidence of relapse
Measured: 1 year post transplant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2014 (estimated)
- Study startJul 2011
- Primary completionMay 2015
- Study completionMay 2015
Why it stopped: Trial closed early due to poor recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeukaemiaStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Collaborators
- Cancer Research UK
- Responsible party
- Sponsor
- Investigators
- Rachael Hough, Principal investigator, University College London Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02310997
- Sponsor's protocol ID
- UCL/09/0128
- Other IDs
- 2009-011818-21, 2009
- Acronym
- MAC UCBT
- Status last verified
- May 2015
- First submitted
- 18 Sep 2014
- Last updated
- 27 May 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen
- ClinicalTrials.gov ID
- NCT02310997
- Acronym / sponsor ID
- MAC UCBT / UCL/09/0128
- Conditions
- Leukaemia, Lymphoma, Other Haematological Diseases
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Trial closed early due to poor recruitment
- Enrolment
- 11 participants (actual)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Collaborators
- Cancer Research UK
- Study start
- Jul 2011
- Primary completion
- May 2015 (actual)
- Study completion
- May 2015 (actual)
- First posted
- 8 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial is looking at using umbilical cord blood from unrelated donors after high dose chemotherapy. It is for people who have cancer of the bone marrow or lymphatic system including leukaemia and lymphoma, or a blood disorder called myelodysplastic syndrome (MDS).
The trial is for babies over 4 weeks old, children, and adults up to the age of 45.
Detailed description
During treatment for cancers of the bone marrow or lymphatic system, a lot of the stem cells are damaged and you may need a bone marrow or stem cell transplant to replace them.
Stem cells can also be collected from the umbilical cord of newborn babies. Many people around the world have donated their baby's umbilical cords which are stored safely.
There are usually enough cells in one cord to transplant a small child, but there may not be enough cells for an older child or adult. Researchers want to see if adults and children can safely have stem cells from more than 1 umbilical cord.
Before a transplant, you have high doses of chemotherapy, sometimes with radiotherapy. This intensive conditioning aims to destroy all the cells in your bone marrow, and is called myeloablative conditioning.
The aim of this trial is to see if a transplant using cord blood cells from unrelated donors after myeloablative conditioning is safe, and whether it helps people who need a stem cell transplant but don't have a stem cell donor.
You may be able to enter this trial if you:
- Have leukaemia, lymphoma or another disorder of the bone marrow and treatment with intensive conditioning followed by a stem cell transplant is likely to help you
- Do not have a suitable stem cell donor in your family, and your doctors have not been able to find a matched unrelated donor
- Have satisfactory blood test results
- Are between 4 weeks and 45 years old
You cannot enter this trial if you:
- Have a family member who could donate stem cells to you, or you have a matched unrelated donor
- Can have any other treatment that your doctors think will cure your disease or keep it under control for a long time
- Have already had a lot of radiotherapy (the trial doctor can advise you about this)
- Have already had a bone marrow or stem cell transplant using your own cells
- Have chronic myeloid leukaemia that is in chronic phase and is responding to imatinib, or is in blast phase and is not responding to treatment Have acute lymphoblastic leukaemia that is not responding to treatment or has come back and more than 5% of your bone marrow is made up of immature cells (blasts)
- Have acute myeloid leukaemia that is not responding to treatment or has come back and more than 20% of your bone marrow is made up of immature cells (blasts)
- Have a disease that has come back and you are having another type of treatment (salvage treatment) but your disease is not responding or is getting worse
- Have a blood disorder called myelofibrosis
- Have a blood disorder called aplastic anaemia
- Have an infection that cannot be controlled with medication
- Have either the HIV or HTLV virus
- Are pregnant or breastfeeding
This phase 2 trial aims to recruit 60 people. It will include both adults and children. Everybody taking part will have intensive conditioning before having a transplant of stem cells from the umbilical cord blood of at least 1 unrelated donor.
To take part in this trial, the researchers need to be sure that there are 2 lots of cord blood cells that would be suitable for you. They will only use cells from 2 cords if there is some concern that they won't get enough cells from 1 umbilical cord.
People aged between 2 and 45 (apart from children under the age of 16 who have acute myeloid leukaemia, juvenile myelomonocytic leukaemia (JMML) or MDS) will have conditioning with fludarabine, cyclophosphamide and radiotherapy to the whole body (total body irradiation). This takes 9 days all together. On the last day, you have the stem cells through a drip into a vein.
Children under 2 years of age (and children up to the age of 16 who have acute myeloid leukaemia, JMML or MDS) will have conditioning with busulfan, cyclophosphamide and melphalan. They do not have radiotherapy. This conditioning takes 10 days all together. They have the stem cells through a drip into a vein on the 11th day.
The stem cells find their way into your bone marrow where they will start making new blood cells.
You will see the trial team and have some tests before you start treatment. The tests include:
- Physical examination
- Blood tests
- Chest X-ray
- Lung function tests
- Heart trace (ECG)
- Heart ultrasound (echocardiogram) or MUGA scan
- Bone marrow test When you have your treatment, you will be in hospital for about 4 to 6 weeks. As you will be at a high risk of infection, you will be in your own room. This is called being in isolation. You have another bone marrow test a month after your transplant.
When you go home, you have to go back to the hospital for regular blood tests. This is likely to be 2 or 3 times a week to begin with. You may have to go back into hospital for a few days at some point.
After a transplant, you will see the doctors and have blood tests At least once a week for the first 3 months At least once a month for the rest of the first year The trial doctors will follow your progress closely for at least 2 years.
The main side effect of the treatment you have just before the transplant is a drop in the number of blood cells, causing an increased risk of infection, tiredness and breathing problems.
We have more information about fludarabine, cyclophosphamide, busulfan and melphalan in our cancer drugs section.
It takes longer for blood cells to start growing again after a transplant of cord blood than after other types of stem cell transplant. Even when your blood count gets back to normal, your immune system may take up to 2 years to recover fully.
Unfortunately, this treatment can affect your ability to have children (your fertility). Men taking part will be offered the option to store sperm (sperm banking) before starting treatment. Preserving fertility for women is more complicated and it is important that women talk to their doctors about this before starting treatment.
After any type of bone marrow or stem cell transplant, there is a risk of graft versus host disease (GVHD). This happens when the new stem cells attack your body tissue. It mainly affects your skin, gut and liver.
Rarely, the new stem cells fail to start working. This is more common with cord blood transplants than with other bone marrow transplants. And even if your transplant is successful, there is a risk your disease may come back. Because of these risks, your doctors will monitor you very closely after your transplant.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fludarabine + Cyclophosphamide + TBI | Experimental | Other: Umbilical Cord Blood Transplant, Drug: Cyclophosphamide, Radiation: Total body irradiation, Drug: FludarabinePatients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising: Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions |
| Busulfan + Cyclophosphamide + Melphalan | Experimental | Other: Umbilical Cord Blood Transplant, Drug: Cyclophosphamide, Drug: Busulfan, Drug: MelphalanPatients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising: Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2 |
Who may qualify
- Ages
- 28 days to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (7 listed)
- Subjects must be < 45 years of age and ≥ 28 days old
- Patients with high risk, advanced or poorly responding haematological disease for which there is published evidence that haematopoietic stem cell transplantation using myeloablative conditioning is likely to be effective
- The individual patient's disease status is such that there is no alternative therapy likely to achieve cure or provide a significant prolongation of disease-free survival
- Left ventricular ejection fraction >45%
- Transaminases and bilirubin < twice the upper limit of the normal range
Key exclusion criteria (11 listed)
- Patients with a suitably matched sibling donor or 10/10 unrelated volunteer donor available within an acceptable time period.
- Pregnancy or breastfeeding.
- Evidence of HIV or HTLV (I+II) infection or known HIV or HTLV positive serology
- Current active serious infection, in particular uncontrolled fungal infection -Previous irradiation that precludes the safe administration of an additional dose of 13- 14.4 Gy of total body irradiation (TBI) in patients aged 2-45 years
- Prior autograft
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Umbilical Cord Blood Transplant | Other | Busulfan + Cyclophosphamide + Melphalan, Fludarabine + Cyclophosphamide + TBI |
| Cyclophosphamide | Drug | Busulfan + Cyclophosphamide + Melphalan, Fludarabine + Cyclophosphamide + TBI |
| Total body irradiation | Radiation | Fludarabine + Cyclophosphamide + TBI |
| Busulfan | Drug | Busulfan + Cyclophosphamide + Melphalan |
| Melphalan | Drug | Busulfan + Cyclophosphamide + Melphalan |
| Fludarabine | Drug | Fludarabine + Cyclophosphamide + TBI |
Primary outcome
Non-relapse mortality at 100 days post transplant
Time frame: 100 days post transplant
5 secondary outcomes
Overall survival at 1 year
Time frame: 1 year post transplant
Time course of mixed chimerism established by the donor graft
Time frame: 28, 60, 100 days, 6 months, 1 year post transplant
Recovery from neutropenia and cytopenia
Time frame: up to 1 year post transplant
Incidence of acute and chronic GVHD
Time frame: 100 Days and 1 year post transplant
Incidence of relapse
Time frame: 1 year post transplant
Results and safety
The study was stopped early (reason given: Trial closed early due to poor recruitment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2015.
Related trials for Leukaemia
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rachael Hough principal investigator
University College London Hospitals
12 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Umbilical Cord Blood Transplant, Cyclophosphamide and Total body irradiation in people with Leukaemia and Lymphoma, run by University College, London at 12 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 27 May 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Trial closed early due to poor recruitment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Non-relapse mortality at 100 days post transplant (time frame: 100 days post transplant). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2015.